Pfizer Indian patent stayed but still on death row
This article was originally published in Scrip
Pfizer has received a minor reprieve in a case concerning the revoked patent for its anticancer, Sutent (sunitinib malate), in India.
You may also be interested in...
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.